Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker Sells 434,478 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 434,478 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the sale, the chief operating officer now owns 1,127,290 shares of the company’s stock, valued at approximately $12,197,277.80. This represents a 27.82 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Eric Venker also recently made the following trade(s):

• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The shares were sold at an average price of $11.06, for a total value of $3,489,673.32.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.

Roivant Sciences Stock Up 0.4 %

Roivant Sciences stock opened at $10.83 on Tuesday. The stock has a 50-day moving average price of $10.79 and a 200 day moving average price of $11.45. The company has a market capitalization of $7.73 billion, a price-to-earnings ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a 52 week low of $9.93 and a 52 week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Research analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently added to or reduced their stakes in ROIV. Natixis Advisors LLC raised its stake in shares of Roivant Sciences by 8.3% during the 3rd quarter. Natixis Advisors LLC now owns 153,717 shares of the company’s stock valued at $1,774,000 after buying an additional 11,726 shares during the last quarter. Swiss National Bank boosted its stake in shares of Roivant Sciences by 1.0% in the third quarter. Swiss National Bank now owns 721,046 shares of the company’s stock worth $8,321,000 after buying an additional 6,900 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Roivant Sciences by 30.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,767,412 shares of the company’s stock worth $31,936,000 after acquiring an additional 646,627 shares during the period. Loomis Sayles & Co. L P raised its position in Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after acquiring an additional 458,601 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Roivant Sciences by 10.8% in the third quarter. The Manufacturers Life Insurance Company now owns 356,600 shares of the company’s stock valued at $4,115,000 after acquiring an additional 34,641 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ROIV shares. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $18.08.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.